Relationship of obesity to adipose tissue insulin resistance.
BMI
insulin resistance
obesity
waist circumference
Journal
BMJ open diabetes research & care
ISSN: 2052-4897
Titre abrégé: BMJ Open Diabetes Res Care
Pays: England
ID NLM: 101641391
Informations de publication
Date de publication:
04 2020
04 2020
Historique:
received:
11
07
2019
revised:
05
01
2020
accepted:
19
01
2020
entrez:
5
4
2020
pubmed:
5
4
2020
medline:
22
6
2021
Statut:
ppublish
Résumé
This study aimed to examine the association of different anatomical forms of obesity with adipose tissue insulin resistance and to assess the diagnostic value and contribution of obesity to adipose tissue insulin resistance. This cross-sectional study included a total of 499 subjects aged 50 years or over. Multivariate regression analysis was conducted to clarify the association of different forms of obesity with adipose tissue insulin resistance (calculated as fasting insulin level×fasting free fatty acids level). Receiver operating characteristic cure analyses were used to assess the diagnostic value of each anthropometric indicator for adipose tissue insulin resistance. Attributable risk per cent and population attributable risk per cent were calculated to assess the contribution of obesity to adipose tissue insulin resistance. After adjustment for potential confounders, we showed that anthropometric indicators were all positively associated with adipose tissue insulin resistance. In males, waist circumference (WC) was the strongest associated factor (OR, 3.43 (95% CI 2.03 to 5.82)) and indicator (area under the curve (AUC): 0.79) of adipose tissue insulin resistance among those indicators. Here, abdominal obesity (WC≥90 cm) accounted for 64.9% of adipose tissue insulin resistance in the abdominal obese males. Accordingly, body mass index (BMI) was the strongest associated factor (OR,3.08 (95% CI 2.04 to 4.66)) and indicator (AUC: 0.78) of adipose tissue insulin resistance in females. Here, general obesity of BMI≥25 kg/m Maintaining WC in males and BMI in females to a normal range could be an important strategy to significantly reduce the occurrence of adipose tissue insulin resistance and the subsequent metabolic diseases.
Identifiants
pubmed: 32245824
pii: 8/1/e000741
doi: 10.1136/bmjdrc-2019-000741
pmc: PMC7254100
pii:
doi:
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Informations de copyright
© Author(s) (or their employer(s)) 2020. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ.
Déclaration de conflit d'intérêts
Competing interests: None declared.
Références
J Diabetes Complications. 2014 Jul-Aug;28(4):470-6
pubmed: 24809931
Front Physiol. 2017 Nov 29;8:965
pubmed: 29238304
Cardiovasc Diabetol. 2016 Apr 19;15:68
pubmed: 27095446
Acta Diabetol. 2019 Feb;56(2):219-226
pubmed: 30637483
Biochim Biophys Acta. 2014 Mar;1842(3):446-62
pubmed: 23707515
Am J Clin Nutr. 2006 Feb;83(2):461S-465S
pubmed: 16470013
Int J Obes (Lond). 2017 Aug;41(8):1288-1294
pubmed: 28465607
Obes Sci Pract. 2017 Aug 08;3(3):272-281
pubmed: 29071103
Hepatology. 2009 Oct;50(4):1087-93
pubmed: 19670459
Diabetes Res Clin Pract. 2015 Apr;108(1):23-30
pubmed: 25700625
Dis Markers. 2016;2016:9085474
pubmed: 28127113
J Endocrinol. 2016 Dec;231(3):R77-R99
pubmed: 27935822
Gend Med. 2009;6 Suppl 1:60-75
pubmed: 19318219
Metab Syndr Relat Disord. 2014 Dec;12(10):503-7
pubmed: 25162912
Diabetes Obes Metab. 2014 Jul;16(7):651-60
pubmed: 24962805
Eur J Endocrinol. 2000 Nov;143(5):657-66
pubmed: 11078990
Front Immunol. 2018 Apr 04;9:659
pubmed: 29670627
Adv Exp Med Biol. 2017;1043:65-86
pubmed: 29224091
Clin Chem. 1972 Jun;18(6):499-502
pubmed: 4337382
Diabetes Metab. 2014 Feb;40(1):16-28
pubmed: 24139247
Curr Opin Clin Nutr Metab Care. 2007 Mar;10(2):142-8
pubmed: 17285001
Diabetes Care. 2019 Feb;42(2):265-272
pubmed: 30455334
Clin Lipidol. 2009 Apr 1;4(2):215-230
pubmed: 20161007
Pediatr Obes. 2014 Oct;9(5):373-80
pubmed: 23861170
Mol Cell Biol. 2015 May;35(10):1686-99
pubmed: 25733684
Diabetes. 2017 Apr;66(4):815-822
pubmed: 28052966
J Clin Endocrinol Metab. 2017 Apr 1;102(4):1193-1199
pubmed: 28323973